{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-032946","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.514958+00:00","generated_at":"2026-06-06T03:33:14.050587+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Express Scripts adds VOQUEZNA to national formularies for commercial plans","bullets":["Express Scripts, a leading U.S. PBM, added VOQUEZNA to its national formularies for commercial plans, effective immediately.","Formulary placement offers access to VOQUEZNA with a single step through a generic proton pump inhibitor (PPI).","Expanded formulary access may drive uptake of Phathom's approved product VOQUEZNA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-032946","json":"https://secwatch.observer/filing/0001193125-24-032946.json","markdown":"https://secwatch.observer/filing/0001193125-24-032946.md","text":"https://secwatch.observer/filing/0001193125-24-032946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524032946/0001193125-24-032946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524032946/d784856d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:33:14.050587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}